Breakthrough Research
The Sinai Center for Thrombosis Research and Drug Development (SCTR), founded by Dr. Paul A. Gurbel in 1998 is recognized in the international cardiology and thrombosis community as a leader in the field of antithrombotic therapy. The expertise of SCTR is centered on anti-platelet and anticoagulant drug development, and laboratory device development to facilitate personalized therapy. The center's primary focus is translational research related to thrombosis in patients undergoing interventional cardiovascular procedures.
The center is equipped with a state-of-the art basic laboratory and located within the Heart Center at Sinai hospital. Renowned for cardiac surgery, cardiology, heart failure, and electrophysiology units, the facility contains a clinical research unit where pharmacodynamic, pharmacokinetic and genetic studies are conducted. Together, these unique characteristics grant the center the capacity to conduct the most intricate investigations of the platelet physiology and coagulation in a diverse population of patients with cardiovascular disease.
The breakthrough findings of SCTR have been published in hundreds of peer-reviewed medical journal articles and have influenced treatment guidelines related to anti-platelet therapy. Original investigations conducted by the Center have been presented nationally and internationally in the most prestigious venues including the American Heart Association and American College of Cardiology Scientific Sessions, the European Congress of Cardiology and the Congress of the International Society on Thrombosis and Haemostasis. Their research has also created a platform for the discovery of new antithrombotic drugs.
Dr. Gurbel and his team have experience in partnering with leading pharmaceutical and medical companies who have sought their expertise. His lab is also funded by NIH.